RxDoctor Payments Data

Walter Flesner, DO

Family Medicine · Cape Coral, FLNPI 1922063742

Payments from drug & device makers

$1,623in general payments, 2019–2025

Across 53 payments — averaging $30.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$341
  • Amgen$276
  • AstraZeneca$141
  • Exact Sciences$131
  • Johnson & Johnson$124
  • AbbVie$117
  • plus $492 from 8 others

What the payments were for

  • Food & beverage$1,623100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,623 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$112,039
Medicare patients
150
Services billed
1,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban36$53,370
XifaxanRifaximin13$49,332
OzempicSemaglutide17$19,403
JardianceEmpagliflozin16$15,155
TrulicityDulaglutide11$8,386
FarxigaDapagliflozin Propanediol11$6,852
SymbicortBudesonide/Formoterol Fumarate15$5,803
Atorvastatin Calcium277$2,563
Metoprolol Succinate126$2,426
ValacyclovirValacyclovir Hcl22$2,423
SynthroidLevothyroxine Sodium35$1,957
Candesartan Cilexetil13$1,637
Levothyroxine Sodium185$1,608
Ventolin HfaAlbuterol Sulfate23$1,433
Omeprazole64$1,243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$108$49,33213 claims
Boehringer IngelheimJardiance$13$15,15516 claims
AstraZenecaFarxiga, Symbicort$141$12,65626 claims
Lilly USA, LLCTrulicity$341$8,38611 claims
AbbVieSynthroid$117$1,95735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Cape Coral

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →